company background image
DRRX

DURECTNasdaqCM:DRRX Stock Report

Market Cap

US$238.9m

7D

11.7%

1Y

-47.0%

Updated

08 Dec, 2021

Data

Company Financials +
DRRX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

DRRX Stock Overview

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs.

DURECT Competitors

Pfizer

NYSE:PFE

US$288.5b

Viatris

NasdaqGS:VTRS

US$15.0b

Teva Pharmaceutical Industries

NYSE:TEVA

US$9.3b

Supernus Pharmaceuticals

NasdaqGM:SUPN

US$1.6b

Price History & Performance

Summary of all time highs, changes and price drops for DURECT
Historical stock prices
Current Share PriceUS$1.05
52 Week HighUS$2.95
52 Week LowUS$0.87
Beta1.16
1 Month Change-19.85%
3 Month Change-17.32%
1 Year Change-46.97%
3 Year Change38.14%
5 Year Change-12.50%
Change since IPO-92.71%

Recent News & Updates

Aug 05
Is DURECT (NASDAQ:DRRX) Using Debt Sensibly?

Is DURECT (NASDAQ:DRRX) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

DRRXUS PharmaceuticalsUS Market
7D11.7%0.3%4.0%
1Y-47.0%10.1%21.7%

Return vs Industry: DRRX underperformed the US Pharmaceuticals industry which returned 10.1% over the past year.

Return vs Market: DRRX underperformed the US Market which returned 21.7% over the past year.

Price Volatility

Is DRRX's price volatile compared to industry and market?
DRRX volatility
DRRX Average Weekly Movement9.9%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.3%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.4%

Stable Share Price: DRRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: DRRX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199879Jim Brownhttps://www.durect.com

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.

DURECT Fundamentals Summary

How do DURECT's earnings and revenue compare to its market cap?
DRRX fundamental statistics
Market CapUS$238.88m
Earnings (TTM)-US$38.07m
Revenue (TTM)US$8.89m

26.9x

P/S Ratio

-6.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DRRX income statement (TTM)
RevenueUS$8.89m
Cost of RevenueUS$31.61m
Gross Profit-US$22.72m
ExpensesUS$15.35m
Earnings-US$38.07m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.17
Gross Margin-255.64%
Net Profit Margin-428.36%
Debt/Equity Ratio32.0%

How did DRRX perform over the long term?

See historical performance and comparison

Valuation

Is DURECT undervalued compared to its fair value and its price relative to the market?

3.73x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate DRRX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate DRRX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DRRX is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: DRRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DRRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DRRX is overvalued based on its PB Ratio (3.7x) compared to the US Pharmaceuticals industry average (2.8x).


Future Growth

How is DURECT forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

74.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DRRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: DRRX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: DRRX's is expected to become profitable in the next 3 years.

Revenue vs Market: DRRX's revenue (71.7% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: DRRX's revenue (71.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DRRX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has DURECT performed over the past 5 years?

2.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DRRX is currently unprofitable.

Growing Profit Margin: DRRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DRRX is unprofitable, but has reduced losses over the past 5 years at a rate of 2.9% per year.

Accelerating Growth: Unable to compare DRRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DRRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: DRRX has a negative Return on Equity (-59.46%), as it is currently unprofitable.


Financial Health

How is DURECT's financial position?


Financial Position Analysis

Short Term Liabilities: DRRX's short term assets ($87.3M) exceed its short term liabilities ($9.6M).

Long Term Liabilities: DRRX's short term assets ($87.3M) exceed its long term liabilities ($24.4M).


Debt to Equity History and Analysis

Debt Level: DRRX has more cash than its total debt.

Reducing Debt: DRRX's debt to equity ratio has reduced from 153.9% to 32% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DRRX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: DRRX has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 3.7% each year.


Dividend

What is DURECT current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DRRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DRRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DRRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DRRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DRRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

Jim Brown (64 yo)

23.83yrs

Tenure

US$1,133,544

Compensation

Dr. James E. Brown, alos known as Jim, D.V.M., serves as Life Science Advisor since 2021 at Kyto Technology and Life Science, Inc. He Co-founded DURECT Corporation in February 1998 and has been its Preside...


CEO Compensation Analysis

Compensation vs Market: Jim's total compensation ($USD1.13M) is about average for companies of similar size in the US market ($USD1.09M).

Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: DRRX's management team is considered experienced (3.9 years average tenure).


Board Members

Experienced Board: DRRX's board of directors are considered experienced (8.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12%.


Top Shareholders

Company Information

DURECT Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: DURECT Corporation
  • Ticker: DRRX
  • Exchange: NasdaqCM
  • Founded: 1998
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$238.881m
  • Shares outstanding: 227.51m
  • Website: https://www.durect.com

Number of Employees


Location

  • DURECT Corporation
  • 10260 Bubb Road
  • Cupertino
  • California
  • 95014-4166
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/08 23:56
End of Day Share Price2021/12/08 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.